UOSD Allergologia e Immunologia Clinica, Dipartimento Scienze Mediche e Chirurgiche Addominali ed Endocrino Metaboliche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Roma, Italy.
Asian Pac J Allergy Immunol. 2023 Dec;41(4):273-291. doi: 10.12932/AP-010423-1582.
Drug reaction with eosinophilia and systemic symptoms (DRESS) and drug-induced liver injury (DILI) can hamper therapeutic strategy, contribute to multiple drug resistance and serious public health burden. Diagnosis (including allergy assessment) and management of these two severe hypersensitivity reactions in clinical practice are somewhat difficult and published scientific evidence is rather weak and limited. The first step is always represented by stopping all anti-tuberculosis (TB) drugs, treating reaction with systemic corticosteroids, and identifying the offending drug, even if it is often complicated by the patient's simultaneous intake of antibiotics. Patch tests and in vitro tests, such as lymphocyte transformation test, could bridge this diagnostic gap, but the available data are scarce and their sensitivity low. The re-challenge test is often necessary but places patients at risk for serious adverse reactions. The desensitization protocols are quite varied and not universally accepted. In this narrative review, we provide an update to the literature data on the management of DRESS and DILI with particular attention to the allergological work-up in the last decade.
药物反应伴嗜酸性粒细胞增多和全身性症状(DRESS)和药物性肝损伤(DILI)可妨碍治疗策略,导致多重耐药,并造成严重的公共卫生负担。在临床实践中,这两种严重超敏反应的诊断(包括过敏评估)和管理有些困难,而且已发表的科学证据相当薄弱且有限。第一步始终是停用所有抗结核(TB)药物,用全身性皮质类固醇治疗反应,并确定致病药物,即使这通常因患者同时服用抗生素而变得复杂。斑贴试验和体外试验,如淋巴细胞转化试验,可以弥补这一诊断空白,但可用数据稀缺且敏感性低。再挑战试验通常是必要的,但会使患者面临严重不良反应的风险。脱敏方案差异很大,尚未被普遍接受。在这篇叙述性综述中,我们提供了过去十年中关于 DRESS 和 DILI 管理的文献数据更新,特别关注过敏学检查。